Steep Hill to Test New Mexico’s Cannabis
- Sep 17, 2015
Steep Hill, the industry leader in cannabis testing and analytics, opened a new cannabis testing and analytics lab in Albuquerque.
“Since New Mexico’s passage of medical cannabis regulations in 2007, the state’s medical cannabis market has become highly accessible to patients. The regulatory requirements being implemented by New Mexico are of the highest caliber and now assure that patients can access safe, tested, and efficacious medicinal cannabis products. This is a real breakthrough for New Mexico that other states will draw inspiration from as they consider regulation in the future,” CEO David Lampach said in a prepared statement.
The New Mexico laboratory is the company’s fifth facility. It is located at 8917 Adams N.E. Steep Hill is working on receiving a fully operational license—at the time it has only provisional approval.
The laboratory is furnished with state-of-the-art equipment designed to screen medical cannabis for both the various active components and the potentially harmful micro-biological contaminants. In the near future the lab will add residual solvent and mycotoxin screening, as required under NMAC 7.34, with other toxin screens following.
The Albuquerque lab will feature the QuantaCann2™ technology, available also for lease to locations throughout New Mexico. Furthermore, the facility will offer consulting and DNA based diagnostic service to licensed producers and patients.
A series of educational lectures on cannabis testing will take place at the Albuquerque lab on September 16th, September 30th and October 7th with national Steep Hill experts Dr. Donald Land, Rev. Kymron DeCesare, and Dr. Reggie Gaudino.
Image courtesy of Steep Hill’s Instagram Page